interim addition topline release good active completed of pleased pre-specified to announce in us Xb and study to moderate-to-severe from first Bryan, colitis. several was Phase product of financial analysis the this Xb Earlier for in our completion today's with on candidates. asthma, of favorable study afternoon, in the of a clinical you, our quarter our GBXXX data its results patients ulcerative XXXX, as include These to eosinophilic pipeline Gossamer to well GBXXX the LEDA of updates Phase Bio as joining from call. everyone Thank day
Beyond of those, we have exciting a to other updates number cover.
So, jump right in. let's
today completed will ongoing We with was studies, completed GBXXX, analysis DPX from pre-specified Xb two-thirds in that antagonist, currently We study, study LEDA of chronic evaluated first rhinosinusitis. have which start study patients the based two on a X our Phase is who asthma eosinophilic oral approximately we the the interim once-a-day announced in the the being either Phase in study. and LEDA of withdrew or which
or reviewed completion. planned continue The results its Independent the Data IDMC, Monitoring to interim from recommended as study and analysis Committee the
As we an given have we blinded study, characterize previously are ongoing is that unable data to further. this stated, the
report data complete when topline is the year. to expect second half We our this in of the study
on totality recommendation, supportive the the data, the to decision analysis commenced the as discussions Based global regulatory as initial planning activities. on X will Gossamer final with well X results of the and determined proceed The Phase and has final Phase IDMC authorities. be to of interim
enrollment. chronic studied rhinosinusitis, treatment previously study the the X also announced which without for in had nasal being Phase has we GBXXX is with TITAN of polyps, both its and completed
of to mitigation potential this the second In expect plans will year. of data a of in COVID-XX. study number have GBXXX, topline this ongoing of our be in conduct our address we implemented study half We challenges proof-of-concept due both studies to
our We affected topline and not for confident pandemic. by monitoring that remote These remain needed. mitigations virtual be the GBXXX direct-to-patient visit, supply study timeline include data drug whenever will
Trademark are of new and not These salt Office this prior XXXX. excited the GBXXX. in We announce due patent also of aspects key development to further property Patent drug [ph] protecting in April claims surrounding studied forms and issued substance clinical to to the being GBXXX a expire States compound that are enhance year, protection of intellectual United the
about rhinosinusitis first-in-class of clinical second potential topline high half GBXXX two to effect diseases. Phase We the in of with remain unmet and need to the oral look enthusiastic studies with treatment sharing and a other difficult-to-treat X patients our from allergic the data in medical We the be of asthma in outcomes chronic asthma year. forward an on moderate-to-severe
are was UC. results and announce therapy were or with the promising four-week safety, we active active Phase GBXXX of GBXXX placebo. X-ASA to to the patients milligram in ulcerative excited study Next, either Xb a This receive with UC. despite study mild-to-moderate solution GBXXX colitis of with randomized patients in from of disease Phase or tolerability assess XXX patients pharmacokinetics to Xb once-daily X:X XX
IBD. As a targeted the reminder, of GBXXX HIF-X is first-in-class a for alpha treatment potential oral stabilizer gut
on such inhibitors, repair the epithelial expression inflammation number a of with integrity. well-known focused the as is with The of the of immunosuppressants, GBXXX support lining antibodies gut. reducing the function of of and liabilities, to stabilization and leads JAK healing alpha designed anti-TNF which genes Unlike safety disrupted associated barrier and corresponding HIF-X
pathways we and GBXXX, in evaluating As addition Phase [ph] into gene with through we initial of [ph] see signs and evaluation entered mucosal healing clinical expression these hoping modifying to such histology. safety tolerability, our of were to study, outcomes, Xb and as
experiencing worsening patient which The most drug was the patients study of of non-related deemed all to who except event events was study, well-tolerated UC, investigator. drug patients adverse case in by dysgeusia, the were on of were mild severity, a All study. nausea. common aside the withdrew from after one for one which completed the in adverse and serious moderate nausea GBXXX for
dosing systemic the significantly GBXXX VEGF a to EPO minimal accumulation in found period on impact was concentrations rapidly levels. gut-targeted clear after four-week of These from consistent profile. compared and the hours are plasma, There was dosing. was or with systemic no in eight over higher gut the plasma had findings
of enhanced such function, Microarray-based evidence gut and in GBXXX with genes as showed the changes tight gut. Claudin-X in profiling of alpha and observed biopsies X barrier also consistent arm. target placebo the an relative arm epithelial other expression engagement junction associated HIF-X to in protein increase mRNA the We stabilization with
a efficacy myeloperoxidase data neither the observe efficacy, also on four-week did this placebo, And compared was study. a for showed neutrophil although immunohistochemistry reduction suggesting evaluated in-patient powered to gut in study Initial trends in we in reduction exploratory outcomes favorable activity. epithelial designed nor first
GBXXX which cases both, arm. in GBXXX in healing While or were instances suggest they seen direct mucosal of GBXXX after epithelial period, two placebo gut sigmoid we cellular clinical receiving XX% XX% Four either study having endoscopic of defined or arm, compared the the or remission action. patients achieved was data achieving encouraging, histological as is to on the XX%. the saw consistent rectum. no the mechanism of level histologic XX healing a remission impact particularly the patients XX and remission receiving the the XX mucosal of a as as patients of in proposed or healing, on the with group, at are and the or rectum GBXXX, placebo in XX of achieved sigmoid These mucosal healing Further both improvement that treatment or in which is short either histologic remission in
in XX%. trials, or in other clinical showing trended arm which receiving efficacy sub-score of also in remission. or receiving patients with GBXXX patients clinical improvement, of seen such patients while in the or XX%. XX as favorable trends patient measures remission, high observed rectal One also receiving compared to of endpoint placebo The XX of arm clinical five to response, GBXXX results was the traditional UC placebo two XX of or XX achieved patients XX% receiving six achieved our We no favorably hurdle GBXXX, bleeding as the compared the in XX%, of XX placebo
from formulation was study. of the cost data ability increase began this Part We'll conference. drug for issues, of present of be clinic. the formulation of After the this future reason drug prior solution doses compound, used. was in-licensing in GBXXX, limiting solution and high a to the our the we that tablet liquid to the medical could we to study the used at in formulation a In a knew of studies developing study this clinical all a immediately and level cyclodextrin tolerability future full
concerns, X we In successfully Phase completed parallel of tolerability in seeing to to solution dose and volunteers the the support able PK form. favorable were a a study, the selection healthy increase that with study, the we formulation. without In to tablet
a to colitis a ulcerative four-week robust results into plan the early and to these induction and Phase evaluating form an with doses non-optimized move the XX-week pandemic. barring advisors half in delays us with Despite dose, short duration unforeseen encouraged the year, of a We are ongoing commence a to our tablet GBXXX promising have study, of study. potentially related X COVID-XX patients second higher the in dosing
mid-teens, We received ranging Gossamer obligations its our to as afternoon option rates reflects unique single $XX our patients lowering IBD. treatment Pharmaceuticals. agreement more also downstream upfront we also potential to remaining from with This for emerge with GBXXX from high-single $XX to license in exchange, paid mid-single million decreased $XXX our to digits. announced Aerpio favorable have Royalties terms, concerning in Gossamer this sales and GBXXX digits royalties upfront net on economic enthusiasm ranging the amended million from including million. and investment a low that to for Aerpio milestone
systemic treatment to disease inhibitor all Inhibitor improving by therapeutic Next, potent of avoiding inhaled the high PDGFR the delivering index. and prior GBXXX GBXXX, hypertension PAH. dry with in the site exposures move arterial upon inhibition to of PAH improve inhaler, let kinase for or convenient the observed us our directly was to powder success on while designed pulmonary with a PDGFR
ranging trial currently an is ongoing dose in patients. studied Phase GBXXX in Xb being PAH
As PK is in this evaluate the GBXXX of safety to the two-week of study patients. profile a reminder, objective and
this encouraging enrollment, an Xb Phase COVID-XX the in was to enrollment given paused. we ongoing temporarily trial While had start pandemic,
enrollment May. potential hearing are from in our restart there We that late is investigators to
have data. gather trial longer keep that we For decided we if the to see open reason, can to additional
guidance shifting the therefore, half QX initial are, data second from our XXXX. study from to the of We for
second have this GBXXX subject enrollment in to developments start-up for to Phase pandemic. activities the of our launched year, study We half X anticipate and the of study related COVID-XX further beginning
a there Phase number excellent proposed received for we investigators tangible on our from plans believe have is We of its X commencement. excitement and building receptivity
Class baseline change patients. Patients the in week This primary baseline PVR week six-minute XX. be therapy study, background secondary the at a XX-week involve will X and XX endpoint endpoint X and on be will stay from at The throughout from including distance prostacyclin. PAH in study Phase key change functional walk will X will
X/X Phase KEYNOTE-AXX for oral to where challenges with as in tumors. observed being on patients toxicities been continues date with of being and GBXXXX, monotherapy the advance patients. track dose with modulator in it tumors, pembrolizumab our to COVID-XX, is the through trial, solid as solid as select new the the CDXXb study well of this combination escalation No trial dose be studied with terms developed all despite chemotherapy or treatment observed continues in in limiting have to in
month XXst. from from suppressor May Poster virtual with Publication solid tumors poster on poster are impact gossamerbio.com we this ASCO the and and Later do action Society at able the Clinical on at to we so, will mechanism that with for available XXth consistent initial therapy myeloid-derived When its the be cells. Virtual and we section. Program will and make our of Meeting, which of website May Oncology PK/PD in Virtual data, the of The XXXX Please early during combination to American both results the lookout Scientific on present safety consists monotherapy pembrolizumab. GBXXXX in are the biomarker data
data In the of from will year. addition, study second present we updated the the half in
now from are received treatment FDA that both the the and designation of we happy to EMA Finally, has pancreatic cancer. GBXXXX for drug the announce orphan
in Jakob this Gossamer the a have San of year on also share. corporate Francisco pursue as his Chief to in Bay of to update oncology area. to Officer closer will be position Dr. Dupont We home opportunities June Medical departing his
clinical the in luck of GBXXXX. endeavors. are development and his We will of Dupont wish future a consultant thankful for the him Dr. and remain Gossamer best support continue for services his to
me Matt Our Senior Smith Presidents, taking Aranda, President, Peterson Heather in will Caryn Vice Dr. Jakob's Richard over join and responsibilities. and Cravets, Vice
the operations in to takes programs partners end, want position, large patients, employees relates of we're ongoing the of a procedures by we our on financial excited portfolio, and Gossamer. and progress due is quickly discuss the seriously. our continue Gossamer that put viral how in of practical in our I at Before Despite COVID-XX, This and further pandemic employees address shared health we it to discuss risks. Gossamer have physical advancement and research unabated, safety focused to limitations place who our to multiple And imposed future incredible to majority the minimize date. to which part including remain the in mission. its
Given strong believe the our and balance tireless efforts sheet, of navigate well our positioned Gossamer employees remains times. these challenging to we
will for Bryan Financial Giraudo, it hand Bio's update. Chief Officer, that, I With Bryan? to over financial Gossamer
